应用染色体微阵列和外显子组测序对孤立性和非孤立性先天性心脏缺陷胎儿进行产前诊断
本研究回顾了上海第一妇婴保健院胎儿医学科2016至2019年经2级超声诊断为先天性心脏病(CHD)的586例胎儿,所有病例均接受染色体微阵列(CMA)作为一线检测,CMA未诊断时行外显子组测序(ES)。84例(14.3%)检出CMA致病性异常,孤立性CHD中为8.8%(35/400),合并其他异常中为26.3%(49/186);47例CMA阴性者行ES,孤立性病例中检出2例(10.5%,2/19),合并其他异常中检出4例(14.3%,4/28)。结论认为应对非孤立性和孤立性心脏异常妊娠均提供CMA侵入性检测,CMA未诊断时ES对两组均有附加诊断价值,即使孤立性CHD也应考虑ES。
要点
- 586例CHD胎儿中CMA致病性异常总检出率为14.3%(84/586)。
- 孤立性CHD的CMA检出率为8.8%(35/400),合并其他异常为26.3%(49/186)。
- CMA阴性后行ES,孤立性CHD检出2例(10.5%,2/19),合并异常检出4例(14.3%,4/28)。
核心结论
- 结论认为,对于合并非孤立性和孤立性心脏异常的妊娠,均应提供CMA侵入性检测。
- 结论认为,当CMA未诊断时,ES在两组中均能增加诊断价值,即使对孤立性CHD胎儿也应考虑ES。
研究设计与样本
- 研究回顾了上海第一妇婴保健院胎儿医学科2016至2019年经2级超声检查诊断为CHD的所有病例记录。
- 病例分为孤立性CHD或合并其他异常或胎儿生长受限。
- 所有病例均接受CMA作为一线遗传学检测,CMA未诊断时行ES。
主要发现
- 586例确诊CHD胎儿中,84例(14.3%)检出CMA致病性异常,其中孤立性CHD为8.8%(35/400),合并其他异常为26.3%(49/186)。
- 47例CMA阴性病例行ES,孤立性病例中检出2例(10.5%,2/19)致病性变异,合并其他异常病例中检出4例(14.3%,4/28)致病性变异。
临床怎么用
- 作者结论认为,应对非孤立性和孤立性心脏异常妊娠均提供CMA侵入性检测。
- 作者结论认为,CMA未诊断时ES可增加诊断价值,即使孤立性CHD胎儿也应考虑ES。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the use of chromosomal microarray (CMA) and Exome sequencing (ES) in fetuses with congenital heart disease (CHD). METHODS: The Fetal Medicine Unit of Shanghai First Maternity and Infant Hospital records were reviewed to ascertain all cases diagnosed with CHD by level 2 ultrasound examination between 2016 and 2019. Cases were categorized as isolated or associated with other abnormalities or fetal growth restriction. CMA was offered to all cases as a first-line genetic test followed by ES when CMA was non-diagnostic. RESULTS: Of the 586 ascertained, 84 (14.3%) had causative CMA abnormality, of which 8.8% (35/400) were in fetuses with isolated CHD and 26.3% (49/186) in those with other abnormalities. ES was performed in 47 cases with a negative CMA. Causative variants were identified in two (10.5%, 2/19) isolated cases and four(14.3%, 4/28) with other abnormalities. CONCLUSION: Invasive procedures with CMA should be offered in pregnancies complicated by both non-isolated and isolated cardiac abnormalities. When CMA is not diagnostic, ES can add diagnostic value in both groups and should be considered even for fetuses with an isolated CHD.
引用
- Xing Y, Zhang Y, Chen J, et al. Prenatal diagnosis for fetuses with isolated and non-isolated congenital heart defects using chromosomal microarray and exome sequencing. Prenat Diagn. 2022. PMID: 35584285. doi:10.1002/pd.6168
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。